It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In this second edition 22 new medications were added so NbN includes now 130 medications.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.

Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.
We also added 4 additional dimensions
4 Additional Dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter
For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.

As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.

它已经很清楚，精神药物的药理目前的命名没有反映我们当代的知识，也没有正确地告知基于神经病学的处方的临床医生。很多时候，我们规定了“焦虑”症或“第二代抗精神病药物”，以抑郁症患者“抗抑郁剂”。
这种做法是令人困惑的。
•五个国际组织ECNP，ACNP，AsCNP，CINP＆IUPHAR决定在五年前成立了一个工作组，并把它嵌入在命名我们目前的神经科学进步的使命。
•范围是包括所有与CNS适应症的药物，并利用这种新的命名，以帮助医生时，他们正试图找出什么将是下一个合理的“neuropsychopharmacological一步”。
•在这第二版中新增了22种新的药物等等的NbN现在包括130周的药物。
这个提议命名旨在反映当前的药理知识基础，并不能一定代表最终的科学道理。
该组装的工作小组可能采取的立场，我们目前的知识基础是不够的，确定的主要目标和正确的行动机制。但作为一个工作小组，我们觉得这是更好地呈现尖端科学解释，而不是等待明确的结论。我们现在需要把我们的病人，直到所有的事实都知道我们不能推迟治疗。
 
因此，该命名是基于：
1.现在需要治疗。
2.更新神经科学的见解。
3.工作队成员的判断。
沿着这些线路，我们已经提出了以下建议：
命名：
药理学和行动模式 - 反映了有针对性的神经递质/分子/系统进行修改和行动的模式/机制目前的认识和了解。
 我们还增加了4个额外的维度
4种其他尺寸：
批准的适应症 - 基于主要监管机构的建议（如FDA，EMA等）
疗效及副作用 - 从正的单，大，RCT和/或“重固体重量”临床数据驱动。只有普遍的或危及生命的副作用被列入
实用注 - 总结了临床知识已被“过滤”，通过专题组“筛子”
神经生物学 - 这方面的重点是生物学。它分为临床前和临床医技科室，并把重点放在后者
对于那些想了解更多ABO从经验data.ut药理得出谁，有一个直接链接到IUPHAR的相关网站 - 我们在这方面的合作者。
 
由于这是正在进行的过程中，我们认识到，该产品是不完美的。 （并考虑到其他高校的反馈）根据大家的反馈新的报告和调查结果，（例如，以后的版本），将进行相应的更新。